Akt1 is frequently upregulated in human tumors, and has been shown to accelerate cell proliferation and to suppress programmed cell death; consequently, inhibiting the activity of Akt1 has been seen as an attractive target for therapeutic intervention. Paradoxically, hyperactivation of the Akt1 oncogene can also prevent the invasive behavior that underlies progression to metastasis. Here we show that overexpression of activated myr-Akt1 in human breast cancer cells phosphorylates and thereby targets the tumor suppressor tuberous sclerosis complex 2 (TSC2) for degradation, leading to reduced Rho-GTPase activity, decreased actin stress fibers and focal adhesions, and reduced motility and invasion. Overexpression of TSC2 rescues the migration phenotype of myr-Akt1-expressing tumor cells, and high levels of TSC2 in breast cancer patients correlate with increased metastasis and reduced survival. These data indicate that the functional properties of genes designated as oncogenes or tumor suppressor genes depends on the context of the cell type and the tissues studied, and suggest the need for caution in designing therapies targeting the function of individual genes in epithelial tissues.
Introduction
Metastasis occurs when cancer cells invade beyond the boundaries of the primary site and establish new tumors in distant organs; because metastases are responsible for most cancer deaths, attention has focused on the mechanisms by which cancer cells acquire invasive metastatic properties (1) . Invasion by cancer cells into surrounding tissues involves alterations in cellular shape and stiffness that facilitate interaction with the new tissue microenvironment (2) , and these modifications depend upon reorganization of the actin cytoskeleton through the action of Rho-GTPases (3). While 22 members of the Rho-GTPase family have been identified, it is the activation of the Rho subfamily that is principally responsible for the assembly of the contractile actomyosin machinery necessary for most types of cell motility (4).
Inhibition of Rho or its effector Rho-kinase (ROCK) significantly compromises cellular migration and invasiveness (5) (6) (7) (8) (9) (10) , and increased expression/activation of Rho and its isoforms has been found in many types of cancers (11) (12) (13) (14) . A recently discovered mechanism for activating Rho in epithelial cells involves the tuberous sclerosis complex 2 gene product, TSC2 (15) .
Tuberous sclerosis complex is a disorder characterized by hamartomas in the skin, kidney, heart, and lung and is caused by inactivating mutations in the tumor suppressor genes TSC1 and TSC2 (16) . Though it has been best characterized as a controller of cell size through its regulation of ribosomal synthesis proteins including ribosomal S6 kinase (17, 18) , TSC2 has been implicated in a number of related signaling pathways in a variety of cell types (19) .
Investigations of MDCK epithelial cells demonstrated that overexpression of TSC2 results in activation of Rho and increased cellular motility (15) , and analysis of TSC2-deficient cells has shown reduced Rho activity (16) , although these effects may depend upon the cell type investigated (20) . While mutational inactivation of TSC2 contributes to tuberous sclerosis complex, regulation of intact TSC2 occurs principally through the action of the serine/threonine kinase Akt1/protein kinase B (21, 22) . Phosphorylation of TSC2 by Akt1 stimulates association with 14-3-3 proteins that mediate subcellular translocation and proteolytic degradation of TSC2 (23) (24) (25) (26) (27) .
Akt1 is one of the most frequently activated protein kinases in human cancer (28, 29) . Activation of Akt1 is associated with resistance to apoptosis, as well as increased cell growth, proliferation, and energy metabolism (28, 30) . Activated Akt1 is correlated with altered cell migration and invasion in several mammalian systems: constitutively active Akt1 or its isoforms can enhance the ability to invade in already invasive cultured cancer cells (31) (32) (33) , but Akt1 can have the opposite effect on normal or less invasive cells (33) .
Moreover, a constitutively active allele of Akt1 blocks ErbB2/Neu-mediated invasion into surrounding tissue and lung metastasis in double transgenic mice (34) . These results reinforce the idea that understanding cell and tissuespecific signaling pathways is critical for evaluating the implications of activated upstream signaling molecules on complex phenotypic effects (35) .
In a study investigating the mechanisms involved in the development of functional mammary epithelial cell structures, we found that signaling pathways activated by phosphatidyl inositol 3-kinase (PI3K) disrupted normal tissue structure by blocking polarity through increased Rac1 activity and stimulating cell proliferation through increased Akt1 activity (36) . We found that cells expressing activated Akt1 showed the expected effects of increased proliferation and resistance to apoptosis, but surprisingly, also appeared to have substantially decreased invasiveness and motility. Here, we show that inhibition of motility by activated Akt1 is dependent upon downregulation of Rho activity. We further show that TSC2 is a key intermediate in this
mechanism, that activated Akt1 inhibits motility by stimulating the degradation of TSC2, and that increased expression of TSC2 can block the invasioninhibitory effects of activated Akt1.
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Results
Activated Akt1 promotes cell proliferation, survival, and tumor growth, but inhibits cell motility and invasion. Akt1 has been implicated in multiple cellular processes, including cell survival, proliferation, growth, and apoptosis resistance (28, 37) . The particular role it plays in a given tissue, however, depends on the model system investigated. We expressed constitutively activated, myristoylated Akt1 (myr-Akt1) (38) and TUNEL immunostaining (Supplemental Figure 2 ). These results demonstrate that Akt1 activation strongly stimulates cell survival and tumor growth in this experimental model. Opposite effects were seen in cell migration, motility, and invasion assays, however. Myr-Akt1 significantly inhibited cell motility in wound healing assays (Fig. 1D) , and by tracking cell location for 24 hours, we found that the motility of isolated myr-Akt1 cells was significantly reduced relative to control cells (Fig. 1E) , which suggests that the decreased migration in the scratch assay is not due to increased cell-cell adhesion. Consistent with these observations, we found that active Akt1 Active Akt1 controls migration and invasion by modulating levels of the tumor suppressor TSC2. In many systems, Akt1 has been shown to phosphorylate TSC2, triggering 14-3-3-dependent proteolytic degradation (16, 19) . Moreover, elevated TSC2 and TSC1 have been shown to increase Rho activity in epithelial MDCK cells (15) and in fibroblasts (47), respectively.
Accordingly, we hypothesized that Akt1-mediated inhibition of Rho activity was the consequence of phosphorylation and downmodulation of TSC2.
Consistent with this possibility, we found increased phosphorylation and decreased total levels of TSC2 in cells expressing myr-Akt1 (Fig. 4A) , and decreased TSC2 expression in myr-Akt1 tumor xenografts (Fig. 4B) . Using immunoprecipitation experiments, we found significantly increased association of TSC2 with 14-3-3 in cells expressing myr-Akt1 (Fig. 4C ).
To determine if exogenous expression of TSC2 could compensate for the inhibition of cell motility and invasion induced by active Akt1, wild type TSC2 was stably expressed in vector control and myr-Akt1 cells (Fig. 4E ).
Functional expression of TSC2 was demonstrated by decreased phosphorylation of p70S6K ( Fig. 4D ) (48) . We found that myr-Akt1 cells expressing TSC2 showed enhanced migration and invasion ( Here, the overexpression of Akt1 (a classical oncogene) leads to larger tumors that are less invasive, and that -given that the majority of mortality resulting from breast cancer is a result of metastatic disease -could potentially lead to a more favorable outcome clinically if occurring in the absence of other tumor-specific modifications (34) . Conversely, increased expression of TSC2 (a classical tumor suppressor) stimulates invasiveness, and correlates with a less favorable clinical outcome ( Figure 5B ). Ongoing efforts to therapeutically target the Akt1 pathway in breast cancer patients (71) might benefit from consideration of TSC2 expression status in the target population, inasmuch as reducing Akt1 activity in tumors expressing high levels of TSC2 could potentially enhance progression to a more malignant phenotype.
Materials and Methods
Cell line, constructs, and antibodies. HMT-3522 mammary epithelial cells were cultured as described previously (40, Immunoblot analysis and Immunoprecipitation. Immunoblot analysis was described previously (72). For immunoprecipitatipn, cells were lysed in IP buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, containing 2 mM NaF, 1 mM sodium orthovanadate, 10 μg/ml leupeptin, 10 μg/ml pepstatin, 10 μg/ml aprotinin, 10 μg/ml E 64, and 1 mM GST-fusion protein pull down assay. The cells were lysed in GST-Fish buffer (10% glycerol, 50 mM Tris pH 7.4, 100 mM NaCl, 1% NP-40, 2 mM MgCl 2 , containing 10 μg/ml leupeptin, 10 μg/ml pepstatin, 10 μg/ml aprotinin, 10 μg/ml E 64, and 1 mM Pefabloc) and centrifuged at 16,000 g at 4°C. Equal amounts of protein supernatants were incubated with recombinant GSTRhotekin or GST-Pak-CD fusion protein-coupled Sepharose beads at 4 °C for 45 min. The beads were washed with an excess of lysis buffer, eluted in sample buffer, and then analyzed by SDS-PAGE and Western blotting using antibody against Rho, Rac1, or Cdc42.
Statistics. All data analysis was performed using Graphpad Prism. Bar 
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Expression of TSC2 rescues cell invasiveness and motility in myr-Akt1 cells.
Graphs display average ± SEM; *, p<0.05; **, p<0.02; ***, p<0.001. 
